<DOC>
	<DOCNO>NCT00135993</DOCNO>
	<brief_summary>Subjects meet diagnosis idiopathic restless legs syndrome ( RLS ) base 4 cardinal clinical feature accord International Restless Legs Syndrome Study Group ( IRLSSG ) allow enroll trial . The primary objective trial demonstrate rotigotine ( SPM 936 ) efficacious subject idiopathic restless legs syndrome . Additional objective investigate safety tolerability rotigotine . Subjects randomize receive either placebo , 1.125 , 2.25 , 4.5 , 6.75mg/day rotigotine 1:1:1:1:1 ( active : placebo ) fashion . Approximately 600 subject enrol trial , participate approximately 60 site . The maximum duration trial approximately 8 month ( consist 4-week Titration Period , 6-month Maintenance Period , 7-day Taper Period , 30-day Safety Follow-Up Period ) .</brief_summary>
	<brief_title>Four Different Transdermal Doses Rotigotine Subjects With Idiopathic Restless Legs Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>Idiopathic restless legs syndrome History sleep disturbance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Idiopathic Restless Leg syndrome</keyword>
</DOC>